Company
.:[TICKER]
Cerrado is a Toronto based gold production, development and exploration company focused on gold projectsin the Americas. The Company is the 100% owner of both the producing Minera Don Nicolás mine in Santa Cruz province, Argentina and the highly prospective development project, Monte Do Carmo located in Tocantins State, Brazil.
170 stories · page 6 of 9
Patents for CelGro® have previously been granted in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand, and the new US divisional patent further protects and strengthens the IP position by providing greater layers of
The East Melbourne location is expected to increase patient access to Emerald Clinics as well as support pivotal registration trials planned for Emyria’s first drug development program, EMD-003.
The grant aims to boost digital health infrastructure in WA and will involve monitoring the vital signs and mental health of at-risk individuals and confirmed COVID-19 individuals.
The Prosthesis list defines the minimum amount of benefit to be paid by private insurers for CelGro®product used in approved dental bone and soft tissue repair procedures.
CelGro represents a breakthrough in soft tissue reconstruction and offers commercial potential in existing addressable markets of bone, tendon, nerve and cartilage, and wider applications in general surgical and soft tissue reconstructive a
The appointment will support Emyria’s multiple mental health focussed initiatives targeting unmet needs in mental health including the initial drug development program - EMD-003 - targeting psychological distress and related problems.
The case study has proven that CelGro®, combined with Ortho-ATI® is effective in returning a patient to normal function and has been published in the International Journal of Case Reports.
It believes the increasing interest and support for high-quality RWE from the FDA, particularly in the field of cannabinoid medicines, bodes well for its strategy to use its proprietary data platform and unique RWE assets to inform and supp
The company grew revenues by 200% from the September 2020 quarter.
The funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals, and to advance the development and commercialisation of Ortho-ATI®.
US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair application, and it will pursue negotiations with multi-national dental companies for ma
The company recently received the green light to introduce its CelGro® collagen medical device into the Australian dental bone and tissue regeneration market.
In parallel to the TGA-registration plan, Emyria will also design its EMD-003 registration studies to meet the requirements of other global regulatory bodies.
The drug programs target major unmet medical needs and will pursue formal registration with major regulators bodies, including the Therapeutic Goods Administration (TGA).
The approval positions Orthocell well for US Food and Drug Administration (FDA) approval, targeted for 2021.
The company has successfully completed the Australian TGA Conformity Assessment process around the safety and performance of CelGro® in dental bone and tissue regeneration procedures.
The company is well-placed to achieve milestones related to registering its leading drug development programs, each addressing a major unmet need - EMD-003 focused on mental health and EMD-004 focused on irritable bowel syndrome (IBS).
With its access to data and clinical care arm, the company is in a unique position to generate clinical evidence for the safety and efficacy of its new cannabis product for mental health applications.
Emyria is undertaking this observational study as an important step towards generating evidence of efficacy and safety for routinely prescribed medicinal cannabis for the management of symptoms in patients with irritable bowel syndrome (IBS
The program is designed to support the registration of a specific cannabinoid-based medicine for a specific mental health indication with the TGA's Australian Register of Therapeutic Goods.
